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Surface modified amorphous nanoporous silica molecules with hydrophobic as well 
as hydrophilic character can be effectively used as therapeutic drug for combating 
chicken malaria in poultry industry. The amorphous nanosilica was developed by 
top-down approach using volcanic soil derived silica as source material. Amorphous 
silica has long been used as feed additive for poultry industry and considered to be 
safe for human consumption by WHO and USDA. The basic mechanism of action of 
these nanosilica molecules is mediated by the physical absorption of VLDL, serum 
triglycerides and other serum cholesterol components in the lipophilic nanopores of 
nanosilica. This reduces the supply of the host derived cholesterol, thus limiting the 
growth of the malarial parasite in vivo.  
 
Avian malaria has a worldwide distribution and is of great economic significance for the 
poultry industry. Organisms such as P. gallinaceum, P. juxtanucleare and P. durae may 
cause up to 90% mortality in poultry. Incidentally, birds with avian malaria have also 
been used as model systems for studying the pathogenesis and treatment of malaria in 
humans1. Coma and death may occur quickly when the parasite burden is high2. 
Experimental infection in Van Cobb breed of the poultry chicken results in peak 
parasitemia five to six days post-infection in 100% birds. Biochemical profiles revealed 
increased serum activities of different classes of cholesterol. Due to strain differences in 
susceptibility, different anti-malarial drugs are usually prescribed3. The major problems 
in such medication schedule are cumbersome dosage, field applicability and cost-
effectiveness. The consumers often turn refractory to the use of these toxic drug 
applications and the possibility of residual toxicity often affects the pricing of the 
broilers. Therefore, there is an urgent need for development of an eco-friendly and better 
therapeutic intervention mechanism for combating malaria in broiler chickens.  
 Apicomplexan parasites Plasmodium falciparum, P. gallinaceum and Toxoplasma gondii 
employ similar strategies for development inside the blood cells of the vertebrate host. 
Parasite-induced synthesis of lipids and depletion of host cholesterol is critical for intra-
erythrocytic proliferation of P. falciparum and Toxoplasma gondii. They utilize to their 
advantage the increased host lipid4-10. In this paper, we demonstrate that surface modified 
hydrophobic as well as lipophilic nanosilica could be effectively used as novel drugs for 
treatment of chicken malaria. Amorphous silica used in this study is considered to be safe 
for human use by WHO and USDA. It has long been used in poultry industry as feed 
additives. Amorphous silica, being hygroscopic and non-lipophilic in nature, could not 
perform the aforementioned additional role as a drug. In order to impart the 
hydrophobicity and lipophilicity as surface characters and also to lower the dose of the 
silica as a proposed drug (by increasing the surface to volume ratio), amorphous silica 
from natural sources like volcanic soil were broken into the nanometer range and then 
surface functionalized.  
 
30 day old Van Cobb breed chicken were artificially infected with P. gallinaceum and 
after seven days they were sacrificed for studying gross pathological changes and are 
reported below. Figure 1 (panel I) shows the enlargement and pigmentation changes in 
the artificially infected chicken [day 7 after infection; sub-panel i(2)] liver vis a vis 
control [day 7; sub-panel i(1)]. Whereas, the panel I sub-panel ii(2) shows the gross 
morphology of the    spleen from the artificially infected chickens (on day 7) vis a vis the 
spleen of the control chickens [panel I, sub-panels: ii(2)]. The study was conducted also 
on other organs like kidney, heart, brain (data not shown). These data show that the 
artificial infection process produced typical changes observed along with the malaria 
infection in chickens. 
 
The number of the different intra-erythrocytic stages of the parasites in chicken blood 
before and after introduction of the nanosilica was counted. Figure 1 Panel II and III 
show the changes in parasite levels in the infected chickens before and after the treatment 
of nanosilica, as determined by the blood smear analysis. The data show that with the 
increase in the parasitemia level, both the intra-erythrocytic stages (trophozoites and 
schizonts) increases and following simultaneous increase typical to the malarial parasite 
development inside the chicken RBC (data from control chicken not shown). But after the 
administration of the nanosilica (marked by red arrows), the number of schizonts go 
down and thereafter the number of trophozoites becomes lesser than in the control (data 
not shown) and as a result total parasite burden is reduced significantly (panel II). This 
shows that due to the presence of the nanosilica in the chicken body, the intra-
erythrocytic stages do not develop properly. Fig 1, panel III, show the researchers 
administering malarial parasite via i. p. (sub-panel A) and i. v. (sub-panel B) route while 
sub-panel C shows the normal chicken (standing) and malaria infected chicken after 5 
days of artificial infection showing signs of posterior paralysis. 
 
Figure 2 shows the changes in the level of different kinds of serum cholesterols as well as 
the total cholesterol content in the control (blue bars) vis a vis malaria infected (pink 
bars) and infected chickens treated with 0.025 mg / ml nanosilica twice a day (orange 
bar). The following table shows the values of the different serum cholesterol components.  
 
Table 1. The different serum cholesterol components as well as the total content were 
measured. In the malaria infected chicken serum, significant increase in the amount of the 
serum cholesterol were observed. On application of nanosilica (0.025 mg/ ml) cholesterol 
levels were found to be reduced back to normal levels.     
 
Cholesterol Types 
(7 days post infection) 
Control 
Chicken 
Serum  
(mgm / dl) 
Malaria 
Infected 
Chicken serum 
(mgm / dl) 
Nanosilica treated 
Malaria Infected 
Chicken serum (mgm / 
dl) 
Serum Cholesterol 130 ± 4.46 194 ± 3.12 151 ± 1.21 
Serum HDL Cholesterol 78 ± 3.01 68 ± 1.1 82 ± 1.86 
Serum LDL Cholesterol 43 ± 2.93 86 ± 2.03 59 ± 2.08 
Serum VLDL Cholesterol 9 ± 1.12 40 ± 2.13 10 ± 1.72 
Serum Triglycerides 31 ± 2.47 225 ± 3.07 39 ± 5.47 
 
 
The results show that during the course of the malaria infection process all the serum 
components increase. VLDL and serum triglycerides are most notable amongst them. But 
after the administration of the lipophilic nanosilica at the particular dose mentioned, the 
levels of these two serum lipids as well as other lipid constituents come back to the 
normal physiological level. This is essential for the quick recovery of the chickens to 
normal health. The application of the higher doses of the nanosilica depletes the 
cholesterol level completely and impedes the process of recovery of the chickens (data 
not shown). As cholesterol is necessary for a number of normal physiological processes, 
maintenance of the requisite physiological level has to be taken into consideration while 
designing the drug dosage. 
 
Figure 3 shows the measurement of changes in the different isoenzymes after the 
administration of the nanosilica in malaria infected chickens and we studied the changes 
in different organs. In all the panels, A represents the level of the isoenzymes in normal 
chicken, B represents the level in the malaria infected chickens while panel C shows the 
level of the same isoenzymes in the infected chickens treated with nanosilica at the 
physiological dose mentioned earlier. It is evident from the data that there are non-
specific changes in the levels of different enzymes tested. This indicates that there will be 
no severe side effects due to the application of the nanosilica as drug to the poultry 
chickens. It could be concluded from these sets of results that malaria infection and 
subsequent treatment by nanosilica brings about organ specific changes in different 
organs of the chickens. We found that 80 ± 3% of the infected chicken (n=15) treated 
with nanosilica recovered from the disease while 100% of the untreated infected chickens 
(n=15) died within 7-10 days of inoculation. The parasite burden was reduced by margin 
of 86±2 % compared to untreated infected birds (n=15). 
 
Drug pool for combating malarial parasite is decreasing day by day due to various genetic 
(viz. generation of drug resistant malarial parasite etc.) and environmental factors (e.g., 
failure of the mosquito eradication programs). Broiler chicken industries are often worst 
hit by the surge of the chicken malaria which causes huge morbidity (affecting the growth 
and thus uniformity of the flock, which finally affects the product pricing and market 
potential) as well as mortality especially in young chickens. Once the poultry industry is 
hit by such a disease, the growers have to use certain standard drugs but consumers face 
the possible side effects of the residual drugs. Therefore a new problem arises and many 
good poultry farms decide the remove the whole stock for fear of losing reputation of 
their brand name and product in the market. In order to avoid this situation, drugs against 
conserved malarial proteins like P0 and SEC65 homologue of P. falciparum11-16 were 
tried. However, a danger of developing auto-immune disease due to the conservation of 
the protein residues between host and parasite proteins will always remain present in this 
approach. We therefore looked for a drug source or lead molecule which has already been 
used by the poultry industry as feed for a long time and is also considered inert in nature. 
Naturally occurring amorphous silica is used by poultry industries for a long time and is 
considered to be safe for human consumption by different regulatory agencies worldwide. 
But the major problem with amorphous silica is its hygroscopic nature; this does not 
allow it to absorb other substances once it absorbs water. In order to circumvent this 
problem, we decided to first increase the surface area by breaking them to the nano-meter 
range and then modify the surface properties described elsewhere in detail17-19. As a 
result, the nanosilica became hydrophobic as well as lipophilic in nature. These 
nanosilica possess nanopores and due to their lipophilic nature they could absorb lipids 
non-specifically via physio-sorption. These particles have been used in the present set of 
experiments as drugs to mop up the excess amount of the host serum cholesterol lipids 
which is used by the malarial parasite mainly for their intra-erythrocytic growth. The 
results show clearly that these nanosilicas at the doses mentioned earlier in the text could 
be used as excellent therapeutic agent against chicken malaria and will be a very valuable 
tool for the broiler industry worldwide. To the best of our knowledge, this report stands 
as a precursor in this area of research worldwide. Furthermore, our preliminary findings 
(A. Rahman et al., unpublished data) also suggest two nanoparticles (AL60102 and 
AL60106; derived from higher plant stem derived nanosilica) are capable of reducing 
certain classes of lipo-proteins (in native form) present in the silkworm larval 
hemolymph. Here, too, infection by nuclear polyhedrosis virus (BmNPV), a scourge in 
silkworm industry enhances the level of certain lipids, part of which is reduced by 
nanosilica. We are now trying to determine the level of nanosilica to be introduced to 
silkworm larval body to maintain the physiological level of these lipoproteins at the 
physiological level. The situation parallels that of chicken malaria and further highlights 
the efficacy of these kinds of surface modified nanosilica. It is tempting however to 
speculate that this chicken and silkworm model for drug development might be used 
successfully for controlling other diseases of insect, animal and human diseases. In 
particular, controlling human malarial parasite growth both in vitro and in vivo might be 
possible16-21. All this may usher in a new era of `metabolomic modulator’ based drug 
development using nanotechnology. 
 
METHODS 
 All the Animal experiments were done in the animal facility of the West Bengal 
University of Animal and Fishery Sciences, West Bengal. 30 day old age matched Van 
Cobb breed broilers weighing approximately 250-300 gms from the M/S Gita Hatcheries 
(Barasat, West Bengal, India) were used throughout the study. The chickens were kept 
individually in standard cage with mosquito net wrapped around for preventing mosquito 
driven infection. The cages were kept in a well ventilated room maintained at 270C. The 
Chickens were provided with standard feed and drinking water manufactured by Gita 
Hatcheries Ltd. and used in the hatchery regularly. Three birds per treatment and age 
matched controls (n=3) were used throughout the study and all protocols were approved 
by the animal ethics committee. Plasmodium gallinaceum Indian isolate frozen stocks 
were purchased from the parasite bank of the National Institute of Malaria Research 
(NIMR), New Delhi. The frozen stocks of the malarial parasite were thawed to 370C and 
mixed with freshly collected chicken blood and parasitemia were determined quickly by 
standard smear technique. Equal volume of chicken blood inoculums (0.2 ml) containing 
less than 0.01% parasitemia were used for artificially infecting chickens via i. p. and i. v. 
injection. The parasitemia were observed by using blood smear examinations. At day 5, 
when the parasitemia were found to be very high, nanosilica dispersed in absolute alcohol 
were fed to the chicken orally (as drops and at the rate of 0.025mg/ml of nanosilica) in 
two doses of 0.5 ml each in the morning (8 am) and evening (8 pm). Higher and lower 
doses were also tried during the course of the treatment, but 0.025 mg /ml of nanosilica 
were found to be physiologically relevant as described in the results section. Data for the 
other doses have not been shown in this paper. Functionalized nanoporous silica were 
prepared from natural sources in collaboration with Fossilshield Inc., Germany, which are 
capable of physically absorbing chicken serum derived lipids (Fig. 1; panel V)17-19.  
 
Standard clinical, post mortem and pathological studies were done on liver, spleen, heart, 
brain and kidney of normal, infected and nanosilica treated infected chicken. These 
studies include changes in the clinical parameters, the gross morphological changes in the 
organs, histopathological studies and post-mortem changes in the aforementioned organs 
vis a vis control. Changes in the concentration of different isoenzymes, viz., peroxidase, 
esterase, lactate de-hydrogenase (LDH) and Glucose-6-phosphate-dehydrogenase.  
Changes in the metabolite levels like aspartate aminotransferase, glutamate 
dehydrogenase, γ-glutamyltransferase and creatinine were also studied. All the protocols 
for measuring isoenzymes and metabolites are described elsewhere in detail20. Serum 
from the control (day 1 and 7) as well as untreated infected birds (day 1 and day 7; after 8 
days of parasite infection, the birds were treated with drugs) and infected chickens treated 
with different concentrations of nanosilica were collected and analyzed for their different 
cholesterol components (total Cholesterol, HDL, LDL, VLDL and serum triglycerides) 
with the professional help of M/S Pathowind Pathological laboratories Inc., India 
(Kolkata, West Bengal, India). Experiments were repeated at least three times in each 
case with at least three birds per treatment. Statistical analyses were performed using 
IRRISTAT software and data were potted following manufacturer’s protocol. 
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